Castle Biosciences CSTL Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $339.92M-2.1% | $344.23M+3.7% | $343.53M+10.1% | $346.27M+20.4% | $347.08M+38.4% | ||
| $75.18M+19.9% | $71.03M+18.0% | $68.9M+22.1% | $65.8M+26.2% | $62.69M+28.8% | ||
| $53.69M+5.6% | $51.85M-0.4% | $50.11M-5.9% | $49.47M-8.2% | $50.82M-4.2% | ||
| $235.6M+12.1% | $229.32M+14.6% | $222.56M+14.6% | $217.15M+15.3% | $210.17M+15.6% | ||
| $8.74M-76.5% | $34.84M+214% | $36.9M+308% | $36.9M+308% | $37.18M+311% | ||
| -$33.29M-141% | -$42.81M-594% | -$34.93M-3,265% | -$23.05M-46.3% | -$13.79M+67.1% | ||
| -9.8%-5.8pp | -12.4%-15.0pp | -10.2%-9.8pp | -6.7%-1.2pp | -4%+12.7pp | ||
| $203K-65.0% | $86K-85.1% | $154K-68.4% | $331K+14.9% | $580K+2,662% | ||
| $11.22M-13.8% | $11.77M-8.9% | $12.25M-3.3% | $12.82M+6.6% | $13.02M+15.4% | ||
| -$295K— | $144K— | $48K— | $0— | —— | ||
| —— | —— | —— | —— | -$1.01M-827% | ||
| -$4.82M— | -$5.36M— | —— | —— | —— | ||
| -$12.83M-153% | -$24.16M-232% | -$12.24M-301% | -$9.47M-205% | -$5.07M+83.5% | ||
| -3.8%-2.3pp | -7%-12.5pp | -3.6%-5.5pp | -2.7%-1.7pp | -1.5%+10.8pp | ||
| -$0.43-126% | -$0.84-235% | -$0.45-314% | -$0.35-169% | -$0.19+83.3% | ||
| -$0.42-180% | -$0.83-226% | -$0.41-286% | -$0.31-158% | -$0.15+86.8% | ||
| 117.5M+1.3% | 116.2M+1.2% | 116.5M+3.6% | 116.8M+6.3% | 116M+7.6% | ||
| 116.9M+4.5% | 115.6M+4.4% | 114.4M+4.2% | 113.1M+4.0% | 111.9M+3.7% | ||
| $373.21M+3.4% | $387.04M+19.7% | $378.46M+20.9% | $369.32M+21.7% | $360.87M+23.3% | ||
| -$295K— | $144K— | $48K— | $0— | —— | ||
| $339.92M-2.1% | $344.23M+3.7% | $343.53M+10.1% | $346.27M+20.4% | $347.08M+38.4% | ||
| -$33.29M-141% | -$42.81M-594% | -$34.93M-3,265% | -$23.05M-46.3% | -$13.79M+67.1% | ||
| -$18.35M-164% | -$2.04M-108% | $7.83M-36.9% | $19.44M+828% | $28.63M+198% | ||
| -$18.35M-164% | -$2.04M-108% | $7.83M-36.9% | $19.44M+828% | $28.63M+198% | ||
| -5.4%-13.6pp | -0.6%-8.0pp | 2.3%-1.7pp | 5.6%+6.5pp | 8.2%+19.9pp | ||
| -$33.29M-141% | -$42.81M-594% | -$34.93M-3,265% | -$23.05M-46.3% | -$13.79M+67.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Castle Biosciences's revenue?
- Castle Biosciences (CSTL) generated $339.9M in revenue over the trailing twelve months, down 2.1% year over year.
- Is Castle Biosciences profitable?
- Castle Biosciences is not currently profitable: it reported a net loss of $12.8M over the trailing twelve months, a -3.8% net margin.
- What are Castle Biosciences's profit margins?
- Gross margin is 77.9% and operating margin is -9.8%, with a -3.8% net margin.
- What is Castle Biosciences's earnings per share?
- Castle Biosciences's diluted EPS over the trailing twelve months is $-0.43.
- Where does Castle Biosciences's income statement data come from?
- Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
